Pub Date : 2026-02-25DOI: 10.1053/j.gastro.2026.02.016
Frank A Sinicrope
{"title":"Advances in Immunotherapy for DNA Mismatch Repair-Deficient Colon and Rectal Cancers.","authors":"Frank A Sinicrope","doi":"10.1053/j.gastro.2026.02.016","DOIUrl":"https://doi.org/10.1053/j.gastro.2026.02.016","url":null,"abstract":"","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":" ","pages":""},"PeriodicalIF":25.1,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-25DOI: 10.1053/j.gastro.2025.11.022
Federica Tavaglione, Juan Vaz, Oveis Jamialahmadi, Luis Antonio Díaz, Veeral Ajmera, Darryl Contrano, Egbert Madamba, Seema Singh, Ricki Bettencourt, Lisa Richards, Hannes Hagström, Rohit Loomba
Background & aims: Phosphatidylethanol (PEth) is a direct, objective alcohol biomarker for detecting excessive alcohol use in steatotic liver disease, including metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD). However, its use in routine clinical practice may be limited by cost and accessibility. This study aimed to develop a novel, accurate, and scalable indirect alcohol biomarker panel to screen for MetALD-ALD in general population settings.
Methods: The derivation cohort consisted of 503 community-dwelling adults with overweight/obesity and steatotic liver disease residing in Southern California, all of whom prospectively underwent magnetic resonance imaging/magnetic resonance elastography assessment and PEth testing. The optimal predictive model was developed using bidirectional stepwise logistic regression and internally validated using 2000 bootstrap samples. The outcome was the presence of MetALD-ALD, defined by incorporating PEth. Model performance was evaluated using area under the receiver operating characteristic curve (AUROC). External validation was conducted in an independent, population-based Swedish cohort of 1777 individuals with available PEth measurements.
Results: In the derivation cohort, the mean (standard deviation) age and body mass index were 51 (13) years and 32.9 (5.8) kg/m2, respectively. The final predictive model, termed the MetALD-ALD Prediction Index (MAPI), included sex, mean corpuscular volume, gamma-glutamyltransferase, high-density lipoprotein cholesterol, and hemoglobin A1c. MAPI demonstrated good performance in both derivation and validation cohorts (AUROC, 0.76 and 0.75, respectively). MAPI was the top-performing model among all commonly used indirect alcohol biomarkers, based on AUROC.
Conclusions: MAPI is a novel, accurate, and scalable biomarker panel for detecting MetALD-ALD. MAPI may guide confirmatory PEth testing in clinical practice and be leveraged in observational cohort studies lacking PEth measurements, as well as in clinical trials.
{"title":"The MetALD-ALD Prediction Index: A Phosphatidylethanol-Driven Biomarker Panel for Identifying Individuals With Steatotic Liver Disease and Excessive Alcohol Use.","authors":"Federica Tavaglione, Juan Vaz, Oveis Jamialahmadi, Luis Antonio Díaz, Veeral Ajmera, Darryl Contrano, Egbert Madamba, Seema Singh, Ricki Bettencourt, Lisa Richards, Hannes Hagström, Rohit Loomba","doi":"10.1053/j.gastro.2025.11.022","DOIUrl":"https://doi.org/10.1053/j.gastro.2025.11.022","url":null,"abstract":"<p><strong>Background & aims: </strong>Phosphatidylethanol (PEth) is a direct, objective alcohol biomarker for detecting excessive alcohol use in steatotic liver disease, including metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD). However, its use in routine clinical practice may be limited by cost and accessibility. This study aimed to develop a novel, accurate, and scalable indirect alcohol biomarker panel to screen for MetALD-ALD in general population settings.</p><p><strong>Methods: </strong>The derivation cohort consisted of 503 community-dwelling adults with overweight/obesity and steatotic liver disease residing in Southern California, all of whom prospectively underwent magnetic resonance imaging/magnetic resonance elastography assessment and PEth testing. The optimal predictive model was developed using bidirectional stepwise logistic regression and internally validated using 2000 bootstrap samples. The outcome was the presence of MetALD-ALD, defined by incorporating PEth. Model performance was evaluated using area under the receiver operating characteristic curve (AUROC). External validation was conducted in an independent, population-based Swedish cohort of 1777 individuals with available PEth measurements.</p><p><strong>Results: </strong>In the derivation cohort, the mean (standard deviation) age and body mass index were 51 (13) years and 32.9 (5.8) kg/m<sup>2</sup>, respectively. The final predictive model, termed the MetALD-ALD Prediction Index (MAPI), included sex, mean corpuscular volume, gamma-glutamyltransferase, high-density lipoprotein cholesterol, and hemoglobin A1c. MAPI demonstrated good performance in both derivation and validation cohorts (AUROC, 0.76 and 0.75, respectively). MAPI was the top-performing model among all commonly used indirect alcohol biomarkers, based on AUROC.</p><p><strong>Conclusions: </strong>MAPI is a novel, accurate, and scalable biomarker panel for detecting MetALD-ALD. MAPI may guide confirmatory PEth testing in clinical practice and be leveraged in observational cohort studies lacking PEth measurements, as well as in clinical trials.</p>","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":" ","pages":""},"PeriodicalIF":25.1,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-25DOI: 10.1053/j.gastro.2026.02.021
Sunil Samnani, Nauzer Forbes
{"title":"Risk of Stomach Cancer with Long-term Use of Proton Pump Inhibitors.","authors":"Sunil Samnani, Nauzer Forbes","doi":"10.1053/j.gastro.2026.02.021","DOIUrl":"https://doi.org/10.1053/j.gastro.2026.02.021","url":null,"abstract":"","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":" ","pages":""},"PeriodicalIF":25.1,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-25DOI: 10.1053/j.gastro.2025.10.029
Hicham Bouchiba, Arthur S. Aelvoet, Mariëtte C.A. van Kouwen, Barbara A.J. Bastiaansen, Tanya M. Bisseling, Alexandra M.J. Langers, Patrick M.M. Bossuyt, Monique E. van Leerdam, Evelien Dekker
Background & Aims
Patients with familial adenomatous polyposis (FAP) are at increased risk of several gastrointestinal and extraintestinal cancers. Although prophylactic surgery has reduced colorectal cancer (CRC) incidence, the lifetime incidence of other cancers has increased. This study assessed the cumulative risks in Dutch FAP patients over the past decades.
Methods
This nationwide cohort study identified FAP patients from the Netherlands Foundation for Detection of Hereditary Tumors national registry and cross-referenced them with the Dutch Pathology Registry. Cumulative cancer incidences between 1975 and 2024 were estimated using the Fine and Gray competing risk method. Standardized incidence ratios (SIRs) were calculated relative to the general population for all cancer types.
Results
A total of 1230 patients (48% women) with FAP were included, of whom 388 (32%) developed a total of 461 cancers. A pathogenic APC variant was identified in 1138 (93%) patients. The most frequently observed cancers were colon (n = 129), rectal (n = 77), duodenal (n = 31), and gastric (n = 28). Since 2020, the observed incidence of gastric cancer has risen to the most commonly diagnosed cancer. SIR analysis showed significantly increased risks for gastrointestinal cancers, including gastric cancer (SIR, 12.02; P < .01), duodenal cancer (SIR, 277.28; P < .01), ampullary cancer (SIR, 113.85; P < .01), CRC (SIR, 14.22; P < .01), small-bowel cancer (SIR, 122.03; P < .01), hepatoblastoma (SIR, 747.52; P < .01), and hepatocellular carcinoma (SIR, 5.43; P = .01). Among extraintestinal cancers, elevated risks were observed for thyroid cancer (SIR, 17.30; P < .01), gynecologic cancers (SIR, 2.27; P < .01), and central nervous system cancers (SIR, 3.79; P < .01).
Conclusions
Despite developments in preventive treatments, individuals with FAP remain at increased risk for multiple cancers, underscoring the need for improved screening and surveillance strategies.
背景和目的家族性腺瘤性息肉病（FAP）患者发生几种胃肠道和肠外癌症的风险增加。虽然预防性手术降低了结直肠癌（CRC）的发病率，但其他癌症的终生发病率却增加了。本研究评估了过去几十年来荷兰FAP患者的累积风险。方法：这项全国性队列研究从荷兰遗传肿瘤检测基金会国家登记处确定FAP患者，并与荷兰病理学登记处交叉参考。1975年至2024年间的累积癌症发病率是用Fine and Gray竞争风险法估计的。计算了所有癌症类型相对于一般人群的标准化发病率（SIRs）。结果共纳入1230例FAP患者（48%为女性），其中388例（32%）共发生461例癌症。在1138例（93%）患者中发现致病性APC变异。最常见的癌症是结肠癌（129例）、直肠癌（77例）、十二指肠癌（31例）和胃癌（28例）。自2020年以来，胃癌的观察发病率已上升为最常见的诊断癌症。SIR分析显示，胃癌（SIR, 12.02; P < 01）、十二指肠癌（SIR, 277.28; P < 01）、腹腹部癌（SIR, 113.85; P < 01）、结直肠癌（SIR, 14.22; P < 01）、小肠癌（SIR, 122.03; P < 01）、肝母细胞瘤（SIR, 747.52; P < 01）和肝细胞癌（SIR, 5.43; P = 0.01）的风险显著增加。在肠外肿瘤中，甲状腺癌（SIR, 17.30; P < 0.01）、妇科癌（SIR, 2.27; P < 0.01）和中枢神经系统癌（SIR, 3.79; P < 0.01）的风险升高。结论：尽管预防性治疗取得了进展，但FAP患者患多种癌症的风险仍在增加，这强调了改进筛查和监测策略的必要性。
{"title":"Incidence of Cancer in Patients With Familial Adenomatous Polyposis in the Netherlands: A Nationwide Cohort Study","authors":"Hicham Bouchiba, Arthur S. Aelvoet, Mariëtte C.A. van Kouwen, Barbara A.J. Bastiaansen, Tanya M. Bisseling, Alexandra M.J. Langers, Patrick M.M. Bossuyt, Monique E. van Leerdam, Evelien Dekker","doi":"10.1053/j.gastro.2025.10.029","DOIUrl":"https://doi.org/10.1053/j.gastro.2025.10.029","url":null,"abstract":"<h3>Background & Aims</h3>Patients with familial adenomatous polyposis (FAP) are at increased risk of several gastrointestinal and extraintestinal cancers. Although prophylactic surgery has reduced colorectal cancer (CRC) incidence, the lifetime incidence of other cancers has increased. This study assessed the cumulative risks in Dutch FAP patients over the past decades.<h3>Methods</h3>This nationwide cohort study identified FAP patients from the Netherlands Foundation for Detection of Hereditary Tumors national registry and cross-referenced them with the Dutch Pathology Registry. Cumulative cancer incidences between 1975 and 2024 were estimated using the Fine and Gray competing risk method. Standardized incidence ratios (SIRs) were calculated relative to the general population for all cancer types.<h3>Results</h3>A total of 1230 patients (48% women) with FAP were included, of whom 388 (32%) developed a total of 461 cancers. A pathogenic <em>APC</em> variant was identified in 1138 (93%) patients. The most frequently observed cancers were colon (n = 129), rectal (n = 77), duodenal (n = 31), and gastric (n = 28). Since 2020, the observed incidence of gastric cancer has risen to the most commonly diagnosed cancer. SIR analysis showed significantly increased risks for gastrointestinal cancers, including gastric cancer (SIR, 12.02; <em>P</em> < .01), duodenal cancer (SIR, 277.28; <em>P</em> < .01), ampullary cancer (SIR, 113.85; <em>P</em> < .01), CRC (SIR, 14.22; <em>P</em> < .01), small-bowel cancer (SIR, 122.03; <em>P</em> < .01), hepatoblastoma (SIR, 747.52; <em>P</em> < .01), and hepatocellular carcinoma (SIR, 5.43; <em>P</em> = .01). Among extraintestinal cancers, elevated risks were observed for thyroid cancer (SIR, 17.30; <em>P</em> < .01), gynecologic cancers (SIR, 2.27; <em>P</em> < .01), and central nervous system cancers (SIR, 3.79; <em>P</em> < .01).<h3>Conclusions</h3>Despite developments in preventive treatments, individuals with FAP remain at increased risk for multiple cancers, underscoring the need for improved screening and surveillance strategies.","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"98 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147278722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-24DOI: 10.1053/j.gastro.2026.01.042
Peter Bossuyt, Jean-Francois Rahier, Filip Baert, Edouard Louis, Elisabeth Macken, Triana Lobaton, Julie Busschaert, Harald Peeters, Pieter Dewint, Denis Franchimont, Barbara Willandt, Christophe Claessens, Laura Vansteenkiste, Olivier Dewit, Marc Ferrante, Séverine Vermeire
Background and Aims
Secondary loss of response to ustekinumab is observed in patients with Crohn’s disease (CD). Multiple dose-intensification regimens have been proposed. We aimed to test prospectively two different dose-intensification regimens with ustekinumab in patients with CD experiencing secondary loss of response.
Methods
This was an investigator-initiated, multicenter, randomized, placebo-controlled trial conducted at 15 hospitals in Belgium. Eligible patients were adults with CD treated with ustekinumab on maintenance dosing of 90 mg subcutaneous q8 weeks and experiencing a secondary loss of response (PRO-2: abdominal pain (AP) score >1 and liquid or very soft stool frequency (SF) >3 and an objective documentation of disease). Patients were randomized 1:1 to receiving a single intravenous re-induction with ustekinumab ≈ 6mg/kg followed by either subcutaneous ustekinumab 90 mg q4 weeks or q8 weeks till week 48. The primary endpoint was the proportion of patients with steroid-free clinical remission at week 48, defined as PRO-2 remission: (AP ≤ 1 AND SF ≤3) and fecal calprotectin <250μg/g and no steroids in the 90 days prior to week 48.
Results
Between March 2020 and October 2023, 108 patients were randomized. Steroid free clinical remission at week 48 was reached in 15% versus 19% of patients in the Q4W versus the Q8W group (difference 4%; p=0.5). Serious adverse events occurred in 17% vs 13% of patients.
Conclusion
In patients with CD and secondary loss of response to ustekinumab, dose-intensification with a single intravenous administration and followed by 4 weekly subcutaneous dosing of ustekinumab was not more effective than one intravenous administration followed by 8 weekly SC dosing of ustekinumab. clinicaltrials.gov number: NCT04245215
{"title":"The effect of dose-intensification after secondary loss of response to ustekinumab in Crohn’s disease: Results of the REScUE study","authors":"Peter Bossuyt, Jean-Francois Rahier, Filip Baert, Edouard Louis, Elisabeth Macken, Triana Lobaton, Julie Busschaert, Harald Peeters, Pieter Dewint, Denis Franchimont, Barbara Willandt, Christophe Claessens, Laura Vansteenkiste, Olivier Dewit, Marc Ferrante, Séverine Vermeire","doi":"10.1053/j.gastro.2026.01.042","DOIUrl":"https://doi.org/10.1053/j.gastro.2026.01.042","url":null,"abstract":"<h3>Background and Aims</h3>Secondary loss of response to ustekinumab is observed in patients with Crohn’s disease (CD). Multiple dose-intensification regimens have been proposed. We aimed to test prospectively two different dose-intensification regimens with ustekinumab in patients with CD experiencing secondary loss of response.<h3>Methods</h3>This was an investigator-initiated, multicenter, randomized, placebo-controlled trial conducted at 15 hospitals in Belgium. Eligible patients were adults with CD treated with ustekinumab on maintenance dosing of 90 mg subcutaneous q8 weeks and experiencing a secondary loss of response (PRO-2: abdominal pain (AP) score >1 and liquid or very soft stool frequency (SF) >3 and an objective documentation of disease). Patients were randomized 1:1 to receiving a single intravenous re-induction with ustekinumab ≈ 6mg/kg followed by either subcutaneous ustekinumab 90 mg q4 weeks or q8 weeks till week 48. The primary endpoint was the proportion of patients with steroid-free clinical remission at week 48, defined as PRO-2 remission: (AP ≤ 1 AND SF ≤3) and fecal calprotectin <250μg/g and no steroids in the 90 days prior to week 48.<h3>Results</h3>Between March 2020 and October 2023, 108 patients were randomized. Steroid free clinical remission at week 48 was reached in 15% versus 19% of patients in the Q4W versus the Q8W group (difference 4%; p=0.5). Serious adverse events occurred in 17% vs 13% of patients.<h3>Conclusion</h3>In patients with CD and secondary loss of response to ustekinumab, dose-intensification with a single intravenous administration and followed by 4 weekly subcutaneous dosing of ustekinumab was not more effective than one intravenous administration followed by 8 weekly SC dosing of ustekinumab. <span><span>clinicaltrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> number: NCT04245215","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"239 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147278749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-24DOI: 10.1053/j.gastro.2026.01.043
Léonard Dubois, Alexandre Chaussard, Philippe Seksik, Stéphane Nancey, Maria Nachury, Xavier Treton, Anthony Buisson, Franck Carbonnel, Mathurin Fumery, Laurent Peyrin-Biroulet, Arnaud Boureille, Xavier Hebuterne, Mélanie Serrero, Edouard Louis, Pierre Blanc, Loic Brot, Nathalie Rolhion, Severine Vermeire, Chaysavanh Manichanh, Reidar Fossmark, Harry Sokol
Background
About 50 to 75% of Crohn’s Disease patients (CD) need bowel resection. Postoperative recurrence of Crohn’s disease is frequent. Here, we investigate the evolution of the mucosa-associated microbiota along the Rutgeerts score measuring endoscopic recurrence after surgery.
Methods
We used 16S rRNA and ITS2 sequencing to profile the mucosa-associated microbiota of biopsies from CD patients at the time of surgery (M0, n=139) and later, at the time of endoscopic assessment of recurrence (M6, n=125).
Results
While the effect of surgery and recurrence were moderate on the overall microbiota composition, we identified specific microbial signatures displaying differential relative abundance when accounting for clinical covariates. The relative abundance of certain species, notably a decrease of Faecalibacterium prausnitzii, or increase of Akkermansia muciniphila, was differentially associated with a whole range of Rutgeerts score or with more specific scores characterizing the inflammation of the anastomosis or the ileum. In addition, machine learning performances were impacted by the consideration of the Rutgeerts score as a multilevel prediction instead of a binary classification, further confirming the need to consider its full range. Finally, we investigated the community dynamics, which highlighted a denser network organisation after surgery and in the absence of recurrence, along with changes in keystone species.
Conclusion
Altogether, these results provide further understanding of the effects of ileal resection patients with CD and show that disease recurrence is a dynamic process characterized by several waves of changes in the microbiota composition.
{"title":"Uncovering the dynamics of mucosa-associated microbiota in post-operative recurrence of Crohn’s disease","authors":"Léonard Dubois, Alexandre Chaussard, Philippe Seksik, Stéphane Nancey, Maria Nachury, Xavier Treton, Anthony Buisson, Franck Carbonnel, Mathurin Fumery, Laurent Peyrin-Biroulet, Arnaud Boureille, Xavier Hebuterne, Mélanie Serrero, Edouard Louis, Pierre Blanc, Loic Brot, Nathalie Rolhion, Severine Vermeire, Chaysavanh Manichanh, Reidar Fossmark, Harry Sokol","doi":"10.1053/j.gastro.2026.01.043","DOIUrl":"https://doi.org/10.1053/j.gastro.2026.01.043","url":null,"abstract":"<h3>Background</h3>About 50 to 75% of Crohn’s Disease patients (CD) need bowel resection. Postoperative recurrence of Crohn’s disease is frequent. Here, we investigate the evolution of the mucosa-associated microbiota along the Rutgeerts score measuring endoscopic recurrence after surgery.<h3>Methods</h3>We used 16S rRNA and ITS2 sequencing to profile the mucosa-associated microbiota of biopsies from CD patients at the time of surgery (M0, n=139) and later, at the time of endoscopic assessment of recurrence (M6, n=125).<h3>Results</h3>While the effect of surgery and recurrence were moderate on the overall microbiota composition, we identified specific microbial signatures displaying differential relative abundance when accounting for clinical covariates. The relative abundance of certain species, notably a decrease of <em>Faecalibacterium prausnitzii,</em> or increase of <em>Akkermansia muciniphila,</em> was differentially associated with a whole range of Rutgeerts score or with more specific scores characterizing the inflammation of the anastomosis or the ileum. In addition, machine learning performances were impacted by the consideration of the Rutgeerts score as a multilevel prediction instead of a binary classification, further confirming the need to consider its full range. Finally, we investigated the community dynamics, which highlighted a denser network organisation after surgery and in the absence of recurrence, along with changes in keystone species.<h3>Conclusion</h3>Altogether, these results provide further understanding of the effects of ileal resection patients with CD and show that disease recurrence is a dynamic process characterized by several waves of changes in the microbiota composition.","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"16 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147278747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-23DOI: 10.1053/j.gastro.2026.02.018
Christopher F.D. Li Wai Suen, Danny Con, Matthew C. Choy, Peter De Cruz
{"title":"Reply to Bourgonje and Mian","authors":"Christopher F.D. Li Wai Suen, Danny Con, Matthew C. Choy, Peter De Cruz","doi":"10.1053/j.gastro.2026.02.018","DOIUrl":"https://doi.org/10.1053/j.gastro.2026.02.018","url":null,"abstract":"","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"2 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147278223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-23DOI: 10.1053/j.gastro.2026.02.012
Enrik John T. Aguila, Edgar Lerma
No Abstract
没有抽象的
{"title":"Visualizing Science in Gastroenterology: The Role of Infographics and Graphical Abstracts in Education, Communication, and Research Dissemination","authors":"Enrik John T. Aguila, Edgar Lerma","doi":"10.1053/j.gastro.2026.02.012","DOIUrl":"https://doi.org/10.1053/j.gastro.2026.02.012","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"17 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147278723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-23DOI: 10.1053/j.gastro.2025.09.053
Arno R. Bourgonje, Paola Mian
No Abstract
没有抽象的
{"title":"Rethinking Infliximab Dosing in Acute Severe Ulcerative Colitis with Model-Informed Precision Dosing","authors":"Arno R. Bourgonje, Paola Mian","doi":"10.1053/j.gastro.2025.09.053","DOIUrl":"https://doi.org/10.1053/j.gastro.2025.09.053","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"46 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146778379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-23DOI: 10.1053/j.gastro.2026.02.017
Martijn R. Jong, Albert J. de Groof, Jacques J.G.H.M. Bergman
No Abstract
没有抽象的
{"title":"Reply to Xu and Mohammed et al.","authors":"Martijn R. Jong, Albert J. de Groof, Jacques J.G.H.M. Bergman","doi":"10.1053/j.gastro.2026.02.017","DOIUrl":"https://doi.org/10.1053/j.gastro.2026.02.017","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"15 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146778385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号